Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Pfizer Consumer relies on Alacer addition; Latin America strong for Bayer OTCs; Allegra Japan launch drives Sanofi OTC growth; Herbalife overcomes investor “noise”; Rx slide offsets Merck OTC gains.
You may also be interested in...
Pfizer Posts Weak First Quarter As It Continues To Mull Over A Split
The Big Pharma disappoints investors with a weak first quarter and a failure to come to any decisions about the future structuring of the company. Meanwhile, the company made little progress of note during the quarter.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.